Clinical Trial Update: A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors [Phase 2]

View source ↗

Summary

Phase 2 proof-of-activity study of Orticumab in subjects with psoriasis and cardiometabolic risk factors completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiometabolic Syndrome
• Coronary Artery Disease
• Inflammation
• Psoriasis

Drugs mentioned

• Orticumab (Orticumab)

Snippet

Sponsor: Abcentra | Conditions: Psoriasis, Inflammation | Phase 2 | Status: COMPLETED